



Tufts Health Care Institute Program on Opioid Risk Management
**Pharmacotherapy for Prescription Opioid Addiction:
 Implications for Pain Management**

June 9-10, 2011
 Hilton Boston Back Bay
 Boston, Mass.

Summit Meeting Objectives:

- To review and update the evidence on the safety and efficacy of pharmacotherapies for prescription opioid abuse and addiction.
- To characterize the public health need for improved recognition and treatment for patients with co-existing pain and opioid addiction.
- To review the management of pain in patients on pharmacologic treatment for opioid addiction.
- To develop a clinical update of pharmacology of treatment of pain for patients with opioid addiction.

Day 1: Thursday, June 9		
Washington Room, 3rd Floor		
7:30 a.m.	Registration and breakfast	
8:00 a.m.	Overview and purpose of the meeting	Nathaniel Katz, MD, MS Program Director
Session 1: Public Health Implications		
8:15 a.m.	The drive to develop medications for prescription opioid abuse: A historical overview of the development of methadone, buprenorphine, and naltrexone	Frank Vocci, PhD Friends Research Institute
8:40 a.m.	Discussion	
Session 2: Epidemiology of Prescription Opioid Abuse/Dependence		
8:50 a.m.	The epidemiology of co-morbid pain and substance abuse	Nathaniel Katz, MD, MS Aaron Gilson, PhD University of Wisconsin-Madison, <i>Co-presenter</i>
9:10 a.m.	Health economics of prescription opioid abuse and its treatment	Howard Birnbaum, PhD Alan White, PhD Analysis Group

9:30 a.m.	Discussion	
Session 3: Evidence for Pharmacotherapy for Prescription Opioid Abuse		
9:45 a.m.	Efficacy of methadone for opioid replacement therapy	Mark Parrino, MPA American Association for the Treatment of Opioid Dependence
10:05 a.m.	Discussion	
10:20 a.m.	Break	
10:40 a.m.	Efficacy of naltrexone for opioid addiction	Sandra Comer, PhD College of Physicians and Surgeons Columbia University
11:15 a.m.	Buprenorphine and methadone in the treatment of pain	Doug Gourlay, MD Mount Sinai Hospital, Toronto
11:45 a.m.	Discussion	
Adams Room A and B, 3rd Floor		
12:00 noon	Lunch	
1:00 p.m.	Efficacy of buprenorphine for prescription opioid addiction	Roger Weiss, MD Harvard Medical School McLean Hospital
1:20 p.m.	Acute and chronic pain management in patients receiving pharmacotherapy for addiction	Daniel Alford, MD Boston University School of Medicine
1:50 p.m.	Discussion	
2:00 p.m.	Guide to the perplexed: How to transition the pain patient with aberrant opioid-related behaviors to addiction treatment	Seddon Savage, MD Dartmouth Medical School
2:20 p.m.	Discussion	
2:30 p.m.	Break	
Session 4: Economic, Clinical and Enforcement Challenges		
2:45 p.m.	Pharmacotherapy for opioid addiction: Drugs in development	Walter Ling, MD UCLA
3:15 p.m.	Discussion	

4:00 p.m.	Concluding remarks	Nathaniel Katz, MD, MS
5:00 p.m.	Meeting of breakout leaders	
Diamond Lounge, 1st Floor		
5:30 – 7:00 p.m.	Reception	

Day 2: Friday, June 10		
Washington Room, 3rd Floor		
7:30 a.m.	Breakfast	
8:00 a.m.	Objectives of Day 2	Nathaniel Katz, MD, MS
8:15 a.m.	Epidemic: Responding to America's Prescription Drug Crisis	Timothy Condon, PhD White House Office of National Drug Control Policy
8:45 a.m.	Law enforcement challenges: Diversion of opioid replacement therapies	Nancy Coffey Drug Enforcement Administration
9:15 a.m.	Regulatory considerations for an opioid analgesic indicated for use in patients with addiction	Deborah Leiderman, MD CNS Drug Consulting LLC
9:45 a.m.	Breakout workgroups	
Madison Room 3rd Floor	Group 1. Review of efficacy and safety of pharmacotherapy for prescription opioid abuse	Walter Ling, MD
Jefferson Room 3rd Floor	Group 2. Review of the management of pain in patients on pharmacotherapy for opioid abuse	Daniel Alford, MD
Lincoln Room 3rd Floor	Group 3. Guide to transitioning pain patients to addiction treatment	Seddon Savage, MD
11:30 a.m.	Break	
11:45 a.m.	Breakout presentations	
12:15 p.m.	Closing review and reflections	Nathaniel Katz, MD, MS
Adams Room A 3rd Floor	Authors' lunch	
12:30-1:30 p.m.		